이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Sensus Healthcare 대차 대조표 상태

재무 상태 기준 확인 6/6

Sensus Healthcare 의 총 주주 지분은 $51.2M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $57.3M 및 $6.1M 입니다. Sensus Healthcare 의 EBIT는 $5.4M 이며 이자보상배율은 -5.7 입니다. $14.7M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	-5.7x
현금	US$14.73m
주식	US$51.21m
총 부채	US$6.07m
총 자산	US$57.27m

최근 재무 상태 업데이트

업데이트 없음

Recent updates

Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up

May 12

Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk

Apr 16

Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 11

There's Been No Shortage Of Growth Recently For Sensus Healthcare's (NASDAQ:SRTS) Returns On Capital

Oct 17

Sensus Healthcare (NASDAQ:SRTS) Might Have The Makings Of A Multi-Bagger

Jul 04

Lacklustre Performance Is Driving Sensus Healthcare, Inc.'s (NASDAQ:SRTS) 26% Price Drop

Mar 14

Analysts Just Made A Captivating Upgrade To Their Sensus Healthcare, Inc. (NASDAQ:SRTS) Forecasts

May 11

Investors Will Want Sensus Healthcare's (NASDAQ:SRTS) Growth In ROCE To Persist

Apr 29

Sensus Healthcare's (NASDAQ:SRTS) Earnings Are Of Questionable Quality

Apr 01

Are Investors Undervaluing Sensus Healthcare, Inc. (NASDAQ:SRTS) By 31%?

Dec 17

We Discuss Why Sensus Healthcare, Inc.'s (NASDAQ:SRTS) CEO Compensation May Be Closely Reviewed

May 30

Sensus Healthcare: Likely Post-Pandemic Sales Recovery Can Boost Share Price

Apr 26

Analysts Expect Breakeven For Sensus Healthcare, Inc. (NASDAQ:SRTS) Before Long

Apr 19

재무 상태 분석

단기부채: SRTS 의 단기 자산 ( $53.9M )이 단기 부채( $5.5M ).

장기 부채: SRTS 의 단기 자산( $53.9M )이 장기 부채( $593.0K ).

부채 대 자본 내역 및 분석

부채 수준: SRTS 부채가 없습니다.

부채 감소: SRTS 5년 전에 부채가 없었습니다.

부채 범위: SRTS 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: SRTS 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Sensus Healthcare 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Independent Director recently sold US$123k worth of stock

Investor sentiment improves as stock rises 69%

Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sensus Healthcare, Inc., Annual General Meeting, May 31, 2024

Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Sensus Healthcare Announces Directors Changes

Sensus Healthcare, Inc. to Report Q4, 2023 Results on Feb 08, 2024

New minor risk - Share price stability

Sensus Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Sensus Healthcare, Inc. Appoints Michael Sardano as A Director, Effective February 1, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

There's Been No Shortage Of Growth Recently For Sensus Healthcare's (NASDAQ:SRTS) Returns On Capital

Sensus Healthcare to Showcase its Full Line of Cutting-Edge Superficial Radiotherapy Devices for the Treatment of Non-melanoma Skin Cancer at ASTRO 2023 in San Diego

New major risk - Earnings quality

Investor sentiment improves as stock rises 31%

Sensus Healthcare, Inc. (NasdaqCM:SRTS) announces an Equity Buyback for $3 million worth of its shares.

Second quarter 2023 earnings: EPS exceeds analyst expectations

New major risk - Share price stability

Sensus Healthcare (NASDAQ:SRTS) Might Have The Makings Of A Multi-Bagger

Independent Director recently bought US$60k worth of stock

Investor sentiment deteriorates as stock falls 37%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 29% to US$10.90

Full year 2022 earnings: EPS misses analyst expectations

Lacklustre Performance Is Driving Sensus Healthcare, Inc.'s (NASDAQ:SRTS) 26% Price Drop

Investor sentiment deteriorates as stock falls 17%

Do Sensus Healthcare's (NASDAQ:SRTS) Earnings Warrant Your Attention?

Now 20% undervalued

Consensus EPS estimates fall by 14%

Investor sentiment deteriorates as stock falls 16%

Full year 2022 earnings: EPS misses analyst expectations

Sensus Healthcare, Inc. Announces Senior Management Appointments and Promotions

Sensus Healthcare, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sensus Healthcare, Inc. to Report Q4, 2022 Results on Feb 09, 2023

Investor sentiment deteriorated over the past week

Price target decreased to US$15.30

Insufficient new directors

Investor sentiment deteriorated over the past week

Price target decreased to US$15.30

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Sensus Healthcare, Inc. Introduces Silk(TM) Laser Hair Removal System

Now 23% undervalued

Sensus Healthcare (NASDAQ:SRTS) Could Become A Multi-Bagger

Now 21% undervalued

President & General Counsel notifies of intention to sell stock

Investor sentiment improved over the past week

Co-Founder recently sold US$521k worth of stock

Sensus Healthcare, Inc. Appoints Mohammad K. Khan to Medical Advisory Board

Now 22% undervalued

Co-Founder notifies of intention to sell stock

Independent Director recently sold US$710k worth of stock

Sensus Healthcare, Inc. Launches Upgrade to its SRT-100 Vision System with New Ultrasound Capabilities

Second quarter 2022 earnings released: EPS: US$0.21 (vs US$0.017 loss in 2Q 2021)

Sensus Healthcare Q2 GAAP EPS, revenue beats

Investor sentiment improved over the past week

Sensus Healthcare: A Buy In Honor Of Skin Cancer Awareness Month

Independent Director recently sold US$75k worth of stock

Consensus revenue estimates increase by 21%

Analysts Just Made A Captivating Upgrade To Their Sensus Healthcare, Inc. (NASDAQ:SRTS) Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investors Will Want Sensus Healthcare's (NASDAQ:SRTS) Growth In ROCE To Persist

Price target increased to US$13.20

Insufficient new directors

Investor sentiment deteriorated over the past week

Sensus Healthcare's (NASDAQ:SRTS) Earnings Are Of Questionable Quality

Investor sentiment improved over the past week

Co-Founder notifies of intention to sell stock

Co-Founder recently sold US$1.4m worth of stock

Empyrean Medical System Inc. acquired Sculptura Assets of Sensus Healthcare, Inc. for $15 million.

Consensus EPS estimates fall by 18%

Price target increased to US$13.10